Skip to main content
TipRanks
Go Ultimate75% OFF

Nanexa AB (NANEXA) Drug Pipeline

2 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Nex-22A, A Prolonged Release Formulation Of LiraglutideType 2 DiabetesPhase ICompletedPhase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2DMay 16, 2024
Nex-20AMultiple MyelomaearlyPhase1CompletedTo Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy SubjectsNov 21, 2022―
Nex-18A Injection, Azacitidine InjectionAcute Myeloid Leukemia (Aml), Myelodysplastic Syndromes (Mds), Chronic Myelomonocytic Leukemia (Cmml)Phase ICompletedPharmacokinetics, Tolerability and Safety of NEX-18aMay 11, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Nanexa AB (SE:NANEXA) have in its pipeline
Nanexa AB SE:NANEXA is currently developing the following drugs: Nex-22A, A Prolonged Release Formulation Of Liraglutide, Nex-20A, Nex-18A Injection, Azacitidine Injection. These drug candidates are in various stages of clinical development as the company works toward FDA approval.